Tackling the challenges of nanomedicines: are we ready?

Hertig, John B; Shah, Vinod P; Flühmann, Beat; Mühlebach, Stefan; Stemer, Gunar; Surugue, Jacqueline; Moss, Rob; Di Francesco, Tiziana

Hertig, John B; Shah, Vinod P; Flühmann, Beat; Mühlebach, Stefan; Stemer, Gunar; Surugue, Jacqueline; Moss, Rob; Di Francesco, Tiziana.

Afiliación

Hertig JB; Department of Pharmacy Practice, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA.
Shah VP; VPS Consulting, North Potomac, MD, USA.
Flühmann B; Vifor Pharma Ltd, Glattbrugg, Switzerland.
Mühlebach S; Division of Clinical Pharmacy & Epidemiology and Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Stemer G; Pharmacy Department, Vienna General Hospital-Medical University Campus, Vienna, Austria.
Surugue J; Hospital Pharmacy Department, Georges Renon General Hospital, Niort, France.
Moss R; Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, Netherlands.
Di Francesco T; Vifor Pharma Ltd, Glattbrugg, Switzerland.

Am J Health Syst Pharm ; 78(12): 1047-1056, 2021 06 07.

Article en En | MEDLINE | ID: mdl-33599767

Asunto(s)

Nanomedicina; Humanos; Equivalencia Terapéutica

Palabras clave

nanomedicine; nanosimilars; pharmacists; substitution; therapeutic equivalency

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nanomedicina Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Am J Health Syst Pharm Asunto de la revista: FARMACIA / HOSPITAIS Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google